Newsletter
Dr. Reddy’s Laboratories is buying the India rights of two hormone therapy medicines, Progynova and Cyclo-Progynova from UK-based Mercury Pharma Group.
The deets: the deal is worth $32.15 million and transfers ownership of the two specialty brands including their trademarks and related rights to Dr. Reddy’s Laboratories.
To put it simply, Dr. Reddy’s now owns these two medicine brands in India and can sell and market them as its own.
Both of these medicines are mainly used by women during or after menopause.
Progynova is a menopause medicine that replaces estrogen to reduce hot flashes and dryness, and helps protect bones.
Cyclo-Progynova is a similar menopause treatment that combines estrogen with another hormone to manage symptoms while keeping the treatment balanced.
What will the company gain: the deal strengthens Dr. Reddy’s women’s health portfolio in India and marks its entry into the hormone replacement therapy market.
The company called it a strategic move into HRT, with Progynova positioned as the lead brand driving its expansion in this segment.
The timing: globally, the HRT market is expected to reach $19 billion in 2026 and grow to $33.7 billion by 2036 at a 5.9% CAGR, driven by aging populations and rising awareness.
In India, HRT sales are projected to grow faster at 7.9% annually, supported by urbanisation, better private healthcare, and increasing awareness of women’s health.
Future Markets Insights
